Endoscopic treatment of vesicoureteral reflux in pediatric patients

Jong Wook Kim, Mi-Mi Oh

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/ hyaluronic acid is the only bulking agent currently approved by the Food and Drug Administration for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been lower than that of open antireflux surgery. However, because injection techniques have been developed, a recent study showed higher success rates of endoscopic treatment than open surgery in the treatment of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, endoscopic treatment is considered a valuable treatment option and viable alternative to long-term antibiotic prophylaxis.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalKorean Journal of Pediatrics
Volume56
Issue number4
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Vesico-Ureteral Reflux
Pediatrics
Therapeutics
Antibiotic Prophylaxis
Hyaluronic Acid
United States Food and Drug Administration
Operative Time
Length of Stay
Costs and Cost Analysis
Injections

Keywords

  • Endoscopy
  • Vesico-ureteral reflux

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pediatrics

Cite this

Endoscopic treatment of vesicoureteral reflux in pediatric patients. / Kim, Jong Wook; Oh, Mi-Mi.

In: Korean Journal of Pediatrics, Vol. 56, No. 4, 01.01.2013, p. 145-150.

Research output: Contribution to journalReview article

@article{810fb9759f6e4488bfa9ea277df1f762,
title = "Endoscopic treatment of vesicoureteral reflux in pediatric patients",
abstract = "Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/ hyaluronic acid is the only bulking agent currently approved by the Food and Drug Administration for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been lower than that of open antireflux surgery. However, because injection techniques have been developed, a recent study showed higher success rates of endoscopic treatment than open surgery in the treatment of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, endoscopic treatment is considered a valuable treatment option and viable alternative to long-term antibiotic prophylaxis.",
keywords = "Endoscopy, Vesico-ureteral reflux",
author = "Kim, {Jong Wook} and Mi-Mi Oh",
year = "2013",
month = "1",
day = "1",
doi = "10.3345/kjp.2013.56.4.145",
language = "English",
volume = "56",
pages = "145--150",
journal = "Korean Journal of Pediatrics",
issn = "1783-1061",
publisher = "Korean Pediatric Society",
number = "4",

}

TY - JOUR

T1 - Endoscopic treatment of vesicoureteral reflux in pediatric patients

AU - Kim, Jong Wook

AU - Oh, Mi-Mi

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/ hyaluronic acid is the only bulking agent currently approved by the Food and Drug Administration for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been lower than that of open antireflux surgery. However, because injection techniques have been developed, a recent study showed higher success rates of endoscopic treatment than open surgery in the treatment of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, endoscopic treatment is considered a valuable treatment option and viable alternative to long-term antibiotic prophylaxis.

AB - Endoscopic treatment is a minimally invasive treatment for managing patients with vesicoureteral reflux (VUR). Although several bulking agents have been used for endoscopic treatment, dextranomer/ hyaluronic acid is the only bulking agent currently approved by the Food and Drug Administration for treating VUR. Endoscopic treatment of VUR has gained great popularity owing to several obvious benefits, including short operative time, short hospital stay, minimal invasiveness, high efficacy, low complication rate, and reduced cost. Initially, the success rates of endoscopic treatment have been lower than that of open antireflux surgery. However, because injection techniques have been developed, a recent study showed higher success rates of endoscopic treatment than open surgery in the treatment of patients with intermediate- and high-grade VUR. Despite the controversy surrounding its effectiveness, endoscopic treatment is considered a valuable treatment option and viable alternative to long-term antibiotic prophylaxis.

KW - Endoscopy

KW - Vesico-ureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=84876488019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876488019&partnerID=8YFLogxK

U2 - 10.3345/kjp.2013.56.4.145

DO - 10.3345/kjp.2013.56.4.145

M3 - Review article

VL - 56

SP - 145

EP - 150

JO - Korean Journal of Pediatrics

JF - Korean Journal of Pediatrics

SN - 1783-1061

IS - 4

ER -